Ritlecitinib: Efficacy Of A Novel Therapy For Severe Alopecia Areata In Patients Aged 12 Years And Older

    December 2025 in “ Actas Dermo-Sifiliográficas ”
    Sergio Vañó‐Galván, I. Figueras-Nart, Carlos Serrano … R Botella-Estrada
    Studysummary This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on sciencedirect.com →
    Discuss this study in the Community →

    Research cited in this study 16

    1. Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the Allegro Clinical Development Programme Journal of the European Academy of Dermatology and Venereology · 2025
    2. A Phase 1, Open-Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata Pediatric Dermatology · 2025
    3. Systematic Review and Indirect Treatment Comparisons of Ritlecitinib Against Baricitinib in Alopecia Areata Journal of the European Academy of Dermatology and Venereology · 2024
    4. Impact of Previous Alopecia Areata Treatment on Efficacy Responses Up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis Dermatology and Therapy · 2024
    5. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program American journal of clinical dermatology · 2024
    6. European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2024
    7. Efficacy and Safety of Ritlecitinib in Adolescents with Alopecia Areata: Results from the ALLEGRO Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Trial Pediatric Dermatology · 2023
    8. Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database Dermatology and therapy · 2023
    9. Alopecia Areata: An Updated Review for 2023 Journal of Cutaneous Medicine and Surgery · 2023
    10. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    11. Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata Drug Design Development and Therapy · 2022
    12. Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study Journal of The American Academy of Dermatology · 2021
    13. Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata JCI insight · 2021
    14. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    15. Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata Drug design, development and therapy · 2018
    16. Inhibiting Janus Kinases to Treat Alopecia Areata Nature medicine · 2014